Breakthroughs in immunotherapy have led to cancer therapeutics that activate the immune system by blocking inhibitory mechanisms. This class of therapeutics has resulted in longer survival rates for cancer patients, some living over 10 years after being diagnosed as terminally ill. However, only a small fraction of patients who receive immunotherapy drugs respond favorably. Recent studies suggest that certain anticancer agents (both cytotoxic chemotherapeutics and targeted drugs) stimulate immune recognition of cancers. Identification of such immunomodulatory anticancer agents would make ideal partners for current immunotherapy treatments, thus increasing the proportion of the treated patients who benefit from immunotherapy. This study aimed to identify the immunomodulatory effects of several anticancer agents by using a novel cell co-culture assay that modeled recognition of breast cancer cells by natural killer cells (NK cells). This physiologically relevant assay was used to systematically characterize effects of anticancer drugs on NK cell function. This assay successfully identified four types of immunomodulatory effects: antagonistic (suppressive), synergistic (enhancing), additive, and no effect on NK cell function. Further investigation confirmed the modulatory effects of those compounds that had been identified as antagonistic or synergistic.
Introduction
Cancer immunotherapy is an emerging field of cancer research, which focuses on developing therapeutics that target the immune system instead of cancer cells. Tumor cells develop immune resistance by taking advantage of inhibitory checkpoint mechanisms. Normally these inhibitory mechanisms are used to prevent the immune system from attacking healthy tissue (autoimmunity). However, cancer cells can cause dysregulation in the expression of inhibitory 'checkpoint' proteins and this can lead to immune resistance. These types of checkpoint mechanisms rely on ligand-receptor interactions and can be blocked by therapeutic antibodies. 1 Among the first such inhibitory receptors to be identified were the Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and Programmed Death 1 (PD-1) receptors. Development of therapeutic antibodies to block these receptors essentially removes the brakes on the immune system and allows the immune system to mount an attack on cancer cells.
A large focus in this field is identifying checkpoint receptors and developing antibody treatments that help activate tumor-cancer recognition, such as Bristol Myers Squibb's anti-CTLA-4 antibody treatment, ipilimumab, for metastatic melanoma.
2 Treatment with immunotherapy therapeutics has produced impressive long term survival of some cancer patients, some living several years after being diagnosed with advanced stages of cancer. However only about 15-20% of treated patients benefit from immunotherapy treatment.
3,4,5,6 For example, ipilimumab only produced long term survival beyond two years in 18% of patients in one clinical trial.
1 A promising solution to increasing the proportion of patients who benefit from treatment is to use immunotherapy in combination with other anti-cancer agents. 7 A study on 502 previously untreated metastatic melanoma patients found that long term survival beyond 3 years was occurring in 20.8% of patients who were assigned to take ipilimumab along with dacarbazine (chemotherapy drug) versus only 12.2% long term survival in patients only receiving dacarbazine. 4 The goal of this study is to identify potential anti-cancer agents that enhance cancer-immune recognition and could be prioritized for used in combination with current cancer immunotherapy treatments. Another goal is to identity which anti-cancer agents suppress cancer-immune recognition, in order to deprioritize them as potential combination partners. Immune-cancer interactions will be modeled using a novel cell co-culture assay that models recognition of breast cancer cells (MDA-MB-231) by natural killer cells (NK cells; a type of effector immune cells). It is predicted that treatment of cancer cells with anti-cancer agents can alter their destruction by natural killer cells in vitro. NK cell activity can be extrapolated from growth inhibition of GFP+ MDA cells when compared to GFP+ MDA cells grown alone. This will allow a better understanding of what immunomodulatory effects anti-cancer agents have on the innate immune system.
Methods

Tissue Culture Breast Cancer Cells
The MDA-MB-231 cell line that overexpresses a green fluorescent protein (GFP) construct was cultured in Dulbecco's modified Eagle medium enriched with 10% fetal bovine serum and 1% pen strep. Cells were incubated at 37°C and 5% CO2.
Natural Killer Cells
Peripheral Blood CD56+ CD16+ Natural Killer Cells, Negative Selection (Lonza, Walkersville, MD) were cultured in LGM-3™ Lymphocyte Growth Medium (Lonza, Walkersville MD) supplemented with 10% Fetal Bovine Serum. Interleukin-2 (IL-2) (PeproTech, Rocky Hill, NJ) was added to NK cell culture at a concentration of 100 units per mL.
High Throughput Screening of Anti-Cancer Agents on MDA NK Cell Co-Culture
Breast cancer cells from cell line MDA-MB-231 were plated in corning black with clear flat bottom 348 well assay plates (Corning Inc., Corning, NY) at a density of 1000 cells per well with a total volume of 50µL, and incubated overnight at 37°C and 5% CO2. The next day compounds were added to the plates using a CyBi-Well Bario 384/60 µL Head (CyBio, Woburn, MA) and 100nL of common anti-cancer agent was added to each well. Anti-cancer agents were obtained from the compound set previously used for the NCI-CTD 2 project (http://www.broadinstitute.org/ctrp.v2/); see Table 3 (in supplemental material) for compounds. The stock concentration for the compounds varied, see Table 3 (in supplemental material) for concentration details. Plates were incubated at 37°C and 5% CO2 overnight. The following day, compound-containing media was removed and natural killer cells (experimental) or LGM3 + IL2 media alone (control) were added at a ratio of 12.5 to 1, NK cells to MDA cells. Assay plates were then incubated for the next 6 days at 37°C and 5% CO2 and imaged daily.
Dose Response Series
Forty selected compounds were serially diluted to 0.333X, 0.111X and 0.0370X the initial concentration (see Table 5 in supplemental material for compounds and detailed concentrations). Breast cancer cells (MDA-MB-231) were plated in 384 well assay plates the same as previously described. After cells adhered overnight, the compounds were added using the same protocol as before. After a 24hour compound treatment, compound media was removed and natural killer cells (experimental) or LGM3 + IL2 (control) were added at a ratio of 12.04 to 1, NK cells to MDA cells. Assay plates were then incubated as described previously.
Testing ABT-737's Synergistic Mechanism
Compounds ABT-737, ABT-199 and SZ4TA2 were obtained from the same CTD 2 collection as before. Initial stock concentration of ABT-737 was 10mM, and was diluted to 5mM in DMSO. Initial stock concentrations of ABT-199 and SZ4TA2 were both 20mM and both compounds were diluted to 2.5mM in DMSO. Cancer cells were plated in 384 well assay plates the same as previously described. After an overnight incubation period, compounds were added as previously described. After a 24 h compound treatment, compound media was removed and NK cells (experimental) or LGM3 + IL2 (control) were added at a ratio of 12 to 1, NK cells to MDA cells. Assay plates were then incubated the same as described before.
Microscopy Imaging
High content microscopy (IXMicro, Molecular Devices) was used to image 384 well plates. Cells were imaged under GFP wavelengths and bright field illumination in order to track MDA cell growth (GFP+ cells) and NK cell activity. Microscope magnification was set at 4X. For the GFP wavelength, exposure was set at 200ms and target max intensity at 50000. For the bright field (transmitted light) wavelength, exposure was set at 200ms, target max intensity at 3000 and Z-offset from GFP was -50µm. Cells were imaged for 6 days (one-time point per day) starting on the day compounds were added. Cells were quantified using MetaXpress software, using a 'Count Nuclei' algorithm. Parameters for this analysis were set at approximate min width 10µm = 6 pixels, approximate max width 20µm = 12 pixels and set to an intensity above local background of 300 graylevels.
Results
Global overview of Compounds Screened in MDA-NK Cell Co-Culture Assay
The immunomodulatory effects of many of the compounds tested in this study have already been identified (see Table 1-3) . Importantly, this study further confirms their immunomodulatory effects and validates this co-culture assay as a tool that can correctly predict immunomodulatory effects. As proof of concept, this study was successfully able to identify the immunomodulatory effects of 320 anti-cancer agents (Table 4) . Of the 320 compounds screened in the MDA-NK cell culture assay more than half (51.56%) of the compounds were manually identified to be additive, which can be seen in Figure 1 . Under this condition the compounds caused a partial reduction in cancer cell growth and this effect combined with the natural killer cells abilities created an additive effect that was the sum of the combined effects. Another observed effect was antagonism which accounted for 12.81% of the compounds screened. Compounds in this group exhibited an immunosuppressive effect i.e. the combined cancer inhibitory effect of the compound and NK cells was less than the cancer inhibitory effect of NK cells alone. The synergistic group of compounds which consisted of 4.69% of the tested compounds, displayed immune enhancing effects, i.e. the combined cancer inhibitory effect of compound and NK cells was far greater than the effects of compound or NK cells alone. The last category to be observed was the group of compounds that had no effect on natural killer cell function and consisted of 30.94% of the compounds screened. Compounds were categorized by manual inspection into four groups: antagonistic, additive, synergistic and having no effect on NK cell activity. Antagonistic compounds exhibited an immunosuppressive effect, while synergistic compounds exhibited immune enhancing effects. Additive compounds demonstrated a combined effect from the compound and NK cells that resulted in a total effect that equaled the sum of the two effects. No effect compounds matched the controls indicating no effect on NK cell activity.
Natural Killer Cells Successfully Inhibit Cancer Cell Growth
When NK cells were co-cultured along with cancer cells, there was an observable difference when compared to cancer cells cultured alone. NK cells cause a reduction in cancer cell growth when compared to the growth of cancer cells alone (Figure 2A ). This indicates that NK cells are capable of killing cancer cells in vitro, without the presence of anti-cancer agents. These results were visually confirmed by comparing the bright field and GFP channel images that correspond to ( Figure  2B ). In the control condition's GFP images, there's an increase in GFP+ cells with each day, which is also reflected in the bright field images. Meanwhile, in the NK cells alone condition's GFP images, there is a reduction of GFP+ cells, indicating cancer cell growth inhibition. In the bright field there is a visible formation of clumps of cancer cells that are surrounded and attacked by NK cells. Identifying the Immunomodulatory Effects Anti-Cancer Agents Have on NK Cell Activity
When pre-treated with compound and co-cultured with NK cells, four effects on cancer cell growth were observed (Figure 3 ). Pifithrin-alpha ( Figure 3A) is an example of a compound with no effect on natural killer cell function. In this figure the condition with compound only matches up closely with the control line, and the NK cell + compound combination condition also matches up with the NK cell only condition, indicating that this compound had no effect on Natural killer cell activity. MK-2206 ( Figure 3B ) is an example of an antagonistic immune suppressive compound. While the compound alone doesn't decrease cancer cell growth, in combination with NK cells cancer growth is greater compared to the NK only condition. This suggests that MK-2206 is immune suppressive. Erlotinib ( Figure 3C ) is an example of an additive compound. In combination with NK cells, erlotinib causes a greater growth suppression of cancer cells compared to the NK cell alone condition. This indicates that Erlotinib combined with NK cells produces an additive effect, which is the sum of the effects of the compound and NK cells on cancer cells. ABT-737 ( Figure 3D ) exhibits effects that are synergistic and immune enhancing. When the compound alone condition is compared to the control condition, there is a similar amount of cancer growth. However, in combination with NK cells there is a dramatic decrease in cancer cell growth when compared to the NK cell alone condition. This suggests that this compound was synergistic with immune cells in mediating cancer cell suppression. 
Microscopy Images Confirm Immunomodulatory Effects
Daily images (GFP and brightfield) were taken for 5 days after 24 h compound pre-treatment at each time interval for each compound. Figure 4 shows the images that correspond to treatments presented in Figure 3 . Figure 4 compares the NK cells only condition with the NK + compound combination condition. Treatment with pifithrin-alpha leads to a similar decrease of GFP+ cells when compared to treatment with NK cells only. This supports the conclusion that pifithrin-alpha had no effect on the ability of NK cells to kill cancer cells ( Figure 4A ). Figure 4B verifies the immunosuppressive effects of MK-2206, where it can be seen that NK cells + MK-2206 leads to an increase of GFP+ cells compared to treatment with NK cells alone. Erlotinib's additive effects on cancer cell growth are illustrated in Figure 4C , where the combination of erlotinib with NK cells leads to a reduction in cancer cell growth compared to NK cells alone. Note that in the bright field images for this drug a pronounced clumping of cancer cells that is absent in the NK cell only treatment. A strong synergistic effect is illustrated for ABT-737 in combination with NK cells on inhibition of cancer cell growth ( Figure 4D ). There was a striking decrease in GFP+ cancer cells in this treatment that is far more pronounced than in any other treatments presented, indicating that ABT-737 is highly immune enhancing. With NK Cells and Pifithrin-Alpha
Dose Response Series Verifies Immune Enhancing and Immune Suppressive Effects
Select compounds were tested in a dose response series, where their modulatory effects were observed at different concentrations. Cells were pre-treated with compound and imaged the same as in the initial drug screen. Figure 5 shows the dose response for two compounds that had been previously seen to be either enhancing or suppressing immune activity. MK-2206 ( Figure 5A ), which was immunosuppressive in the initial drug screen, was found to be immunosuppressive at all concentrations when compared to the DMSO control with no compound (0 µM concentration condition). This confirms MK-2206's immunosuppressive effects towards NK cell activity. ABT-737 ( Figure 5B ) was previously seen to be immune enhancing and synergistic in the initial drug screen, and this effect was confirmed across various concentrations when compared to the DMSO control. Although these compounds were able to demonstrate their modulatory effects at all concentrations, they were most effective at higher concentrations. 
Exploring Synergistic Mechanism of ABT-737
ABT-737 is an inhibitor of several proteins in the BCL family, including BCL-2, BCL-xl and BCL-w. In order to investigate the potential mechanism by which ABT-737 is synergistic, ABT-199 and SZ4TA2 (BCL selective compounds) were tested alongside ABT-737. ABT-199 is a selective inhibitor of BCL-2, and SZ4TA2 is a selective inhibitor of BCL-xL. While the effects of ABT-737 in this trial were similar to previous experiments (compare Figure 3D, 6A) , neither of the other BCL family inhibitors exhibited this synergistic effect ( Figure 6B, C) . This indicates that both ABT-199 and SZ4TA2 have no effect on natural killer cell activity.
Discussion
We were successfully able to determine that treatment of cancer cells with anti-cancer agents does alter their destruction by natural killer cells in vitro. Some of these compounds such as erlotinib are already in clinical trials as combination partners with current immunotherapy treatments (www.clinicaltrials.gov, identifier NCT02013219). In addition to identifying known immunomodulatory effects, this study was able to identify many unknown immunomodulatory effects. Compounds identified as synergistic or immune enhancing (4.69%) should be given priority when considering potential immunotherapy combination partners. While compounds that were identified as antagonistic or immune suppressive (12.81%) should be deprioritized when considering potential immunotherapy combination partners. This study also identified most of the (A) ABT-737 (10µM) which inhibits BCL-2, BCL-xl and BCL-W was compared to two compounds that selectively inhibit certain proteins in the BCL-2 family. (B) ABT-199 (5µM) is selectively inhibits BCL-2, while (C) SZ4TA2 (5µM) selectively inhibits BCL-xL. Synergistic effects of ABT-737 were confirmed, while both ABT-199 and SZ4AT2 showed no effect.
compounds as additive (51.56%). However, further investigation into these compounds is required to determine if they would make good combination partners with immunotherapy.
Another important aspect that this study uncovered was successfully modeling cancer immune interactions in vitro. This study confirmed that NK cells are able to destroy breast cancer cells in vitro. As a result of this ability, we were able to use this assay to determine the immunomodulatory effects of anti-cancer agents. This study was successfully able to identify four types of immunomodulatory effects: antagonistic, synergistic, additive, and no effect on NK cell activity. Examples of such identified compounds include MK-2206 (antagonistic), ABT-737 (synergistic), erlotinib (additive), and pifithrin-alpha (no effect). And a dose response series of select compounds was able to confirm their immunomodulatory effects. For example, the effect of MK-2206 as immunosuppressive was confirmed at all tested concentrations, and the immune enhancing effect of ABT-737 was also confirmed. Despite demonstrating immunomodulatory effects at low concentrations, the compounds all seemed to be most effective at higher concentrations. Some additional aspects that need to be considered in future studies are the effects of the tumor microenvironment; specifically, the immunosuppressive effects of the tumor microenvironment. In order to make this assay more physiologically relevant, immunosuppressive cells (such as stromal cells) would need to be introduced, and the effects of the compounds would need to be monitored. Other types of cancer cells would also need to be tested in order to see if these immunomodulatory effects are specific to breast cancer or if they can by generalized to other types of cancer.
By identifying immunomodulatory effects, we can make new hypotheses on mechanisms that make compounds immunosuppressive or immune enhancing. One such mechanism that we further investigated was the mechanism that made ABT-737 synergistic. ABT-737 is a compound that inhibits BCL-2, BCL-xL and BCL-W, and the BCL-2 protein family is associated with regulating cell death. Dysregulation or overexpression of the BCL-2 family can inhibit cell death pathways and lead to malignancies. 8 Therefore inhibiting BCL-2 family proteins has the potential to stimulate apoptosis under certain conditions and thus prevent potential cancerous or pre-cancerous cells from becoming malignant. In order to determine which member of the BCL-2 family was causing synergism, two selective compounds were tested side by side to ABT-737. ABT-199 is a selective inhibitor of BCL-2 and SZ4TA2 is a selective inhibitor of BCL-xL. It was found that neither of these compounds had any immunomodulatory effects, indicating that BCL-2 and BCL-xL alone do not cause synergistic effects. This suggests that synergism may either be caused by BCL-W or by combining the inhibitory effects of two or all three of these BCL-2 family proteins. Further studies would need to combine compounds and introduce a BCL-W selective inhibitor in order to fully determine the mechanism that makes ABT-737 synergistic.
Conclusion
This study confirms the usefulness of a co-culture assay of NK cells and cancer cells as an in vitro method to screen potential anti-cancer agents. We successfully identified certain compounds as suppressive or enhancing which will be useful for prioritizing and deprioritizing immunotherapy combination partners. The usefulness of this in vitro assay was illustrated by confirming previously known modulatory effects such as erlotinib's additive effect that resulted in greater reduction of cancer cell growth or survival. In addition, the assay identified previously unknown effects such as MK-2206's suppressive effects and ABT-737's enhancing effects on NK cell activity. Despite these promising findings, further research is needed to finish testing all the known anti-cancer agents, to see the effects that the tumor microenvironment has on anti-cancer agent's immunomodulatory effects and to see if these effects are specific to breast cancer cells or if they can be generalized to more cancers. 
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